There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allogene Therapeutics (ALLO – Research Report) and Generation Bio (GBIO – Research Report) with bullish sentiments.
Allogene Therapeutics (ALLO)
In a report released today, Sami Corwin from William Blair maintained a Buy rating on Allogene Therapeutics. The company’s shares closed last Monday at $2.90, close to its 52-week low of $2.23.
According to TipRanks.com, Corwin is a 2-star analyst with an average return of
Allogene Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $13.27, implying a 375.6% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
Generation Bio (GBIO)
In a report released today, Gil Blum from Needham maintained a Buy rating on Generation Bio, with a price target of $10.00. The company’s shares closed last Monday at $2.84.
According to TipRanks.com, Blum is a 3-star analyst with an average return of
Generation Bio has an analyst consensus of Moderate Buy, with a price target consensus of $8.00, a 160.6% upside from current levels. In a report released today, Wedbush also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALLO:
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
- ALLO Upcoming Earnings Report: What to Expect?
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
- Allogene awarded $15M grant from CIRM to support ALLO-316 development
